CN108686220A - A kind of antitumor agent for thyroid cancer - Google Patents
A kind of antitumor agent for thyroid cancer Download PDFInfo
- Publication number
- CN108686220A CN108686220A CN201810767920.4A CN201810767920A CN108686220A CN 108686220 A CN108686220 A CN 108686220A CN 201810767920 A CN201810767920 A CN 201810767920A CN 108686220 A CN108686220 A CN 108686220A
- Authority
- CN
- China
- Prior art keywords
- antitumor agent
- babinet
- thyroid cancer
- agent
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
The invention discloses a kind of antitumor agents for thyroid cancer, kill agent by antitumor agent, tumor cell proliferation inhibitor, tumour cell for the antitumor agent of thyroid cancer and Nasopharyngeal neoplasms inhibitor forms, dispensing percentage is:Antitumor agent 20%~40%, tumor cell proliferation inhibitor 20%~25%, tumour cell kills agent 20%~25%, Nasopharyngeal neoplasms inhibitor 20%~25%, antitumor agent is by free crataegolic acid, erythrodiol, uvaol, betulinic acid, betuline and cellobiose composition, the antitumor agent for thyroid cancer in the present invention is by antitumor agent, tumor cell proliferation inhibitor, tumour cell kills agent and Nasopharyngeal neoplasms inhibitor composition, it can play and tumor cell proliferation is inhibited, Nasopharyngeal neoplasms are inhibited and are killed the effect of tumour cell, effectively increase therapeutic effect of this antitumor agent to thyroid cancer, it brings glad tidings for the health of people.
Description
Technical field
The present invention relates to antitumor agent technical fields, specially a kind of antitumor agent for thyroid cancer.
Background technology
Thyroid cancer is most common thyroid malignancy, accounts for about the 1% of whole body malignant tumour, including papillary carcinoma,
Four kinds of filter blocking cancer, undifferentiated carcinoma and cephaloma histological types, it is relatively low with grade of malignancy, the preferable papillary carcinoma of prognosis is most common,
In addition to cephaloma, most thyroid cancers originate from follicular epithelial cells, and antitumor drug is the one kind for treating tumor disease
Drug has chemotherapeutics, biological agent in brief, and in recent years, the development of molecular weight tumor, molecular pharmacology keeps tumour essential
It gradually illustrates, the invention of extensive quickly screening, combinatorial chemistry, genetic engineering etc. advanced technologies and application acceleration drug
Development process, the research and development of antitumor drug have been enter into a brand-new epoch, but existing antitumor agent its to first shape
The therapeutic effect of gland cancer is undesirable, can not ensure the health of people, for this purpose, it is proposed that a kind of for the anti-of thyroid cancer
Tumour agent.
Invention content
The purpose of the present invention is to provide a kind of antitumor agents for thyroid cancer, to solve to carry in above-mentioned background technology
The problem of going out.
To achieve the above object, the present invention provides the following technical solutions:A kind of antitumor agent for thyroid cancer, for
The antitumor agent of thyroid cancer kills agent and Nasopharyngeal neoplasms by antitumor agent, tumor cell proliferation inhibitor, tumour cell
Inhibitor forms, and dispensing percentage is:Antitumor agent 20%~40%;Tumor cell proliferation inhibitor 20%~25%;It is swollen
Oncocyte kills agent 20%~25%;Nasopharyngeal neoplasms inhibitor 20%~25%.
Preferably, the antitumor agent is by free crataegolic acid, erythrodiol, uvaol, betulinic acid, betuline and fiber two
Sugar composition, and the disaccharides that cellobiose is 2 glucose molecules being keyed by β Isosorbide-5-Nitraes, chemical formula C12H22O11。
Preferably, the tumor cell proliferation inhibitor is by free crataegolic acid, erythrodiol, malol, uvaol, birch
Acid, betuline and 1,5-AF composition.
Preferably, the tumour cell kill agent by free crataegolic acid, erythrodiol, malol, uvaol, betulinic acid,
Betuline and the carbohydrate composition in addition to cellulose derivative, and the carbohydrate in addition to cellulose derivative is mannitol or sugarcane
Sugar.
Preferably, the Nasopharyngeal neoplasms inhibitor is inhibited by free crataegolic acid, erythrodiol, uvaol, MARCKS-
Property compound, betuline and ascopyrone P composition, and MARCKS- inhibitory compounds are peptides, and peptide has ammonia selected from the group below
Base acid sequence:SEQ ID NO:1 to SEQ ID NO:231,SEQ ID NO:234 and SEQ ID NO:235;The ends N of peptide sequence
End and/or C-terminal amino acid are optionally through chemical modification.
Preferably, preparation method includes the following steps:
A, antitumor agent, tumor cell proliferation inhibitor, tumour cell are killed into agent and Nasopharyngeal neoplasms inhibitor according to rule
Fixed dispensing percentage, which is added in blender, to be stirred;
B, within the scope of 20~35 DEG C, mixing time controls between 1~1.5h control blender temperature;
C, after the completion of stirring, filling process is carried out to it;
D, packaging and storage after the assay was approved.
Preferably, the blender includes babinet 1, and the middle-end of 1 intracavity bottom of babinet is embedded with heating plate 7,1 inner cavity of babinet
Bottom and be embedded with heat-conducting plate 12 positioned at the upper end of heating plate 7, the surrounding of 1 bottom of babinet has been fixedly connected with sleeve 11, and
The top of 11 inner cavity of sleeve is connected with support leg 10 by spring 8, and the bottom of support leg 10 is movably installed with idler wheel 9, case
The upper end on 1 right side of body is installed with bubbler 13, and the outlet side of bubbler 13 is connected by the bottom on 1 right side of pipeline and babinet
Logical, the middle-end at 1 top of babinet is installed with motor 14, and the output shaft of motor 14 is fixedly connected with shaft 4, shaft 4 it is outer
Surface is fixedly connected with paddle 5.
Preferably, the heat-conducting plate 12 is conductive graphite piece or thermal conductive silicon offset plate, and the upper surface of heat-conducting plate 12 and babinet 1
The bottom of inner cavity is concordant, and list is movably installed at the pipeline connected between the bottom on 1 right side of outlet side and babinet of bubbler 13
To valve, the left end at 1 top of babinet offers feed inlet 2, and the right end at 2 top of feed inlet has been connected through hinge activity cover board,
The upper end in the left side of babinet 1 is fixedly connected with controller 3, and the outer surface of controller 3 motor that is fixedly connected sequentially from back to front is opened
Close 31, bubbler switch 32 and temperature control button 33, and three output ends of controller 3 respectively with motor switch 31, bubbling
Device switch 32 and the input terminal of temperature control button 33 are electrically connected, the output end of motor switch 31 and the input terminal electricity of motor 14
Property connection, the input terminal electric connection of the output end of bubbler switch 32 and bubbler 13, the output end of temperature control button 33
It is electrically connected with the input terminal of heating plate 7, the bottom in 1 left side of babinet offers discharge port 6, and the inner surface activity of discharge port 6
Valve is installed.
Compared with prior art, beneficial effects of the present invention are as follows:
The antitumor agent for thyroid cancer in the present invention is killed by antitumor agent, tumor cell proliferation inhibitor, tumour cell
Dead agent and Nasopharyngeal neoplasms inhibitor composition, can play tumor cell proliferation is inhibited, Nasopharyngeal neoplasms press down
System and the effect for killing tumour cell, effectively increase therapeutic effect of this antitumor agent to thyroid cancer, are the strong of people
Health brings glad tidings.
Description of the drawings
Fig. 1 is dispensing table schematic diagram of the present invention;
Fig. 2 is blender structural schematic diagram of the present invention;
Fig. 3 is agitator controller structural schematic diagram of the present invention.
In figure:1 babinet, 2 feed inlets, 3 controllers, 31 motor switch, 32 bubblers switch, 33 temperature control buttons, 4 turns
Axis, 5 paddles, 6 discharge ports, 7 heating plates, 8 springs, 9 idler wheels, 10 support legs, 11 sleeves, 12 heat-conducting plates, 13 bubblers, 14 electricity
Machine.
Specific implementation mode
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation describes, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.It is based on
Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts every other
Embodiment shall fall within the protection scope of the present invention.
Please refer to Fig.1-3, a kind of antitumor agent for thyroid cancer, for thyroid cancer antitumor agent by antitumor
Agent, tumor cell proliferation inhibitor, tumour cell kill agent and Nasopharyngeal neoplasms inhibitor composition, can play to tumour cell
Proliferation is inhibited, Nasopharyngeal neoplasms are inhibited and kill the effect of tumour cell, effectively increases this antitumor agent
To the therapeutic effect of thyroid cancer, bring glad tidings for the health of people, dispensing percentage is:Antitumor agent 20%~40%;
Tumor cell proliferation inhibitor 20%~25%;Tumour cell kills agent 20%~25%;Nasopharyngeal neoplasms inhibitor 20%
~25%.
Antitumor agent is made of free crataegolic acid, erythrodiol, uvaol, betulinic acid, betuline and cellobiose, and fine
Dimension disaccharides is the disaccharides for 2 glucose molecules being keyed by β Isosorbide-5-Nitraes, chemical formula C12H22O11。
Tumor cell proliferation inhibitor by free crataegolic acid, erythrodiol, malol, uvaol, betulinic acid, betuline and
1,5-AF forms.
Tumour cell kills agent by free crataegolic acid, erythrodiol, malol, uvaol, betulinic acid, betuline and removes fibre
Carbohydrate composition other than the plain derivative of dimension, and the carbohydrate in addition to cellulose derivative is mannitol or sucrose.
Nasopharyngeal neoplasms inhibitor is by free crataegolic acid, erythrodiol, uvaol, MARCKS- inhibitory compounds, birch
The wooden brain and ascopyrone P composition, and MARCKS- inhibitory compounds are peptides, peptide has amino acid sequence selected from the group below:
SEQ ID NO:1 to SEQ ID NO:231,SEQ ID NO:234 and SEQ ID NO:235;N-terminal and/or the C end of peptide sequence
Terminal amino acid is optionally through chemical modification.
Preparation method includes the following steps:
A, antitumor agent, tumor cell proliferation inhibitor, tumour cell are killed into agent and Nasopharyngeal neoplasms inhibitor according to rule
Fixed dispensing percentage, which is added in blender, to be stirred;
B, within the scope of 20~35 DEG C, mixing time controls between 1~1.5h control blender temperature;
C, after the completion of stirring, filling process is carried out to it;
D, packaging and storage after the assay was approved.
Blender includes babinet 1, and the middle-end of 1 intracavity bottom of babinet is embedded with heating plate 7, the bottom and position of 1 inner cavity of babinet
It is embedded with heat-conducting plate 12 in the upper end of heating plate 7, the surrounding of 1 bottom of babinet has been fixedly connected with sleeve 11, and 11 inner cavity of sleeve
Top support leg 10 is connected with by spring 8, the bottom of support leg 10 is movably installed with idler wheel 9,1 right side of babinet it is upper
End is installed with bubbler 13, and the outlet side of bubbler 13 is connected to by pipeline with the bottom on 1 right side of babinet, and babinet 1 pushes up
The middle-end in portion is installed with motor 14, and the output shaft of motor 14 is fixedly connected with shaft 4, and the outer surface of shaft 4, which is fixed, to be connected
It is connected to paddle 5, heat-conducting plate 12 is conductive graphite piece or thermal conductive silicon offset plate, and the upper surface of heat-conducting plate 12 and 1 inner cavity of babinet
Bottom is concordant, and check valve, case are movably installed at the pipeline connected between the bottom on 1 right side of outlet side and babinet of bubbler 13
The left end at 1 top of body offers feed inlet 2, and the right end at 2 top of feed inlet has been connected through hinge activity cover board, and babinet 1 is left
The upper end of side is fixedly connected with controller 3, and the outer surface of controller 3 is fixedly connected sequentially from back to front motor switch 31, drum
Bubbler switch 32 and temperature control button 33, and three output ends of controller 3 respectively with motor switch 31, bubbler switch 32
It being electrically connected with the input terminal of temperature control button 33, the output end of motor switch 31 is electrically connected with the input terminal of motor 14,
The output end of bubbler switch 32 is electrically connected with the input terminal of bubbler 13, the output end and heating plate of temperature control button 33
7 input terminal is electrically connected, and the bottom in 1 left side of babinet offers discharge port 6, and the inner surface of discharge port 6 is movably installed with valve
Door.
In use, the antitumor agent for thyroid cancer is killed by antitumor agent, tumor cell proliferation inhibitor, tumour cell
Dead agent and Nasopharyngeal neoplasms inhibitor composition, can play tumor cell proliferation is inhibited, Nasopharyngeal neoplasms press down
System and the effect for killing tumour cell, effectively increase therapeutic effect of this antitumor agent to thyroid cancer, are the strong of people
Health brings glad tidings.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
Understanding without departing from the principles and spirit of the present invention can carry out these embodiments a variety of variations, modification, replace
And modification, the scope of the present invention is defined by the appended.
Claims (8)
1. a kind of antitumor agent for thyroid cancer, it is characterised in that:For thyroid cancer antitumor agent by antitumor agent,
Tumor cell proliferation inhibitor, tumour cell kill agent and Nasopharyngeal neoplasms inhibitor composition, and dispensing percentage is:It is anti-swollen
Tumor agent 20%~40%;Tumor cell proliferation inhibitor 20%~25%;Tumour cell kills agent 20%~25%;Tumour cell
Transfer inhibitor 20%~25%.
2. a kind of antitumor agent for thyroid cancer according to claim 1, it is characterised in that:The antitumor agent by
Free crataegolic acid, erythrodiol, uvaol, betulinic acid, betuline and cellobiose composition, and cellobiose is by β Isosorbide-5-Nitrae keys
The disaccharides of 2 glucose molecules of connection, chemical formula C12H22O11。
3. a kind of antitumor agent for thyroid cancer according to claim 1, it is characterised in that:The tumour cell increases
Inhibitor is grown by free crataegolic acid, erythrodiol, malol, uvaol, betulinic acid, betuline and 1,5-AF group
At.
4. a kind of antitumor agent for thyroid cancer according to claim 1, it is characterised in that:The tumour cell kills
Dead agent is by free crataegolic acid, erythrodiol, malol, uvaol, betulinic acid, betuline and the sugar in addition to cellulose derivative
Class forms, and the carbohydrate in addition to cellulose derivative is mannitol or sucrose.
5. a kind of antitumor agent for thyroid cancer according to claim 1, it is characterised in that:The tumour cell turns
Inhibitor is moved by free crataegolic acid, erythrodiol, uvaol, MARCKS- inhibitory compounds, betuline and ascopyrone P
Composition, and MARCKS- inhibitory compounds are peptides, peptide has amino acid sequence selected from the group below:SEQ ID NO:1 to SEQ ID
NO:231,SEQ ID NO:234 and SEQ ID NO:235;The N-terminal and/or C-terminal amino acid of peptide sequence are optionally through chemistry
Modification.
6. a kind of antitumor agent for thyroid cancer according to any one of claims 1 to 5, it is characterised in that:It is made
Preparation Method includes the following steps:
A, antitumor agent, tumor cell proliferation inhibitor, tumour cell are killed into agent and Nasopharyngeal neoplasms inhibitor according to rule
Fixed dispensing percentage, which is added in blender, to be stirred;
B, within the scope of 20~35 DEG C, mixing time controls between 1~1.5h control blender temperature;
C, after the completion of stirring, filling process is carried out to it;
D, packaging and storage after the assay was approved.
7. a kind of antitumor agent for thyroid cancer according to claim 6, it is characterised in that:The blender includes
Babinet 1, the middle-end of 1 intracavity bottom of babinet are embedded with heating plate 7, the bottom of 1 inner cavity of babinet and are embedded positioned at the upper end of heating plate 7
There is heat-conducting plate 12, the surrounding of 1 bottom of babinet has been fixedly connected with sleeve 11, and the top of 11 inner cavity of sleeve passes through 8 activity of spring
It is connected with support leg 10, the bottom of support leg 10 is movably installed with idler wheel 9, and the upper end on 1 right side of babinet is installed with bubbler
13, and the outlet side of bubbler 13 is connected to by pipeline with the bottom on 1 right side of babinet, the middle-end at 1 top of babinet is installed with
Motor 14, and the output shaft of motor 14 is fixedly connected with shaft 4, the outer surface of shaft 4 is fixedly connected with paddle 5.
8. a kind of antitumor agent for thyroid cancer according to claim 7, it is characterised in that:The heat-conducting plate 12 is
Conductive graphite piece or thermal conductive silicon offset plate, and the upper surface of heat-conducting plate 12 is concordant with the bottom of 1 inner cavity of babinet, the outlet of bubbler 13
Check valve is movably installed at the pipeline connected between the bottom on 1 right side of end and babinet, the left end at 1 top of babinet offers charging
Mouth 2, and the right end at 2 top of feed inlet has been connected through hinge activity cover board, the upper end in 1 left side of babinet is fixedly connected with controller
3, the outer surface of controller 3 is fixedly connected sequentially from back to front motor switch 31, bubbler switch 32 and temperature control button
33, and three output ends of controller 3 respectively with motor switch 31, the input terminal of bubbler switch 32 and temperature control button 33
It is electrically connected, the output end of motor switch 31 is electrically connected with the input terminal of motor 14, the output end and drum of bubbler switch 32
The input terminal of bubbler 13 is electrically connected, and the output end of temperature control button 33 is electrically connected with the input terminal of heating plate 7, babinet 1
The bottom in left side offers discharge port 6, and the inner surface of discharge port 6 is movably installed with valve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810767920.4A CN108686220A (en) | 2018-07-13 | 2018-07-13 | A kind of antitumor agent for thyroid cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810767920.4A CN108686220A (en) | 2018-07-13 | 2018-07-13 | A kind of antitumor agent for thyroid cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108686220A true CN108686220A (en) | 2018-10-23 |
Family
ID=63850547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810767920.4A Pending CN108686220A (en) | 2018-07-13 | 2018-07-13 | A kind of antitumor agent for thyroid cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108686220A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB629988A (en) * | 1947-08-26 | 1949-10-03 | Western States Machine Co | Improvements in or relating to stirring and heat transfer devices |
| CN1450900A (en) * | 2000-07-31 | 2003-10-22 | 日清奥利友株式会社 | Antitumor agents |
| CN1871227A (en) * | 2003-10-28 | 2006-11-29 | 日本淀粉工业株式会社 | Antitumoral agent |
| CN103764152A (en) * | 2012-08-24 | 2014-04-30 | 可克意株式会社 | Anti-tumor agent |
| CN105517562A (en) * | 2013-04-05 | 2016-04-20 | 拜欧马可医药公司 | Inhibitors of metastasis |
| CN107376714A (en) * | 2017-09-11 | 2017-11-24 | 苏州发百纺织有限公司 | One kind printing and dyeing agitating device |
-
2018
- 2018-07-13 CN CN201810767920.4A patent/CN108686220A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB629988A (en) * | 1947-08-26 | 1949-10-03 | Western States Machine Co | Improvements in or relating to stirring and heat transfer devices |
| CN1450900A (en) * | 2000-07-31 | 2003-10-22 | 日清奥利友株式会社 | Antitumor agents |
| CN1871227A (en) * | 2003-10-28 | 2006-11-29 | 日本淀粉工业株式会社 | Antitumoral agent |
| CN103764152A (en) * | 2012-08-24 | 2014-04-30 | 可克意株式会社 | Anti-tumor agent |
| CN105517562A (en) * | 2013-04-05 | 2016-04-20 | 拜欧马可医药公司 | Inhibitors of metastasis |
| CN107376714A (en) * | 2017-09-11 | 2017-11-24 | 苏州发百纺织有限公司 | One kind printing and dyeing agitating device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | DNAzyme‐loaded metal–organic frameworks (MOFs) for self‐sufficient gene therapy | |
| Mei et al. | Photothermal‐controlled nanotubes with surface charge flipping ability for precise synergistic therapy of triple‐negative breast cancer | |
| Li et al. | Inducing endoplasmic reticulum stress to expose immunogens: A DNA tetrahedron nanoregulator for enhanced immunotherapy | |
| Priyadarshani et al. | Achieving reversible H2/H+ interconversion at room temperature with enzyme-inspired molecular complexes: A mechanistic study | |
| Hosono et al. | Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells | |
| Liu et al. | Calixarene‐Embedded Nanoparticles for Interference‐Free Gene–Drug Combination Cancer Therapy | |
| Zhu et al. | Near‐Infrared Nano‐Optogenetic Activation of Cancer Immunotherapy via Engineered Bacteria | |
| CN104277134B (en) | A kind of preparation method and applications of the dictyophora fungus polysaccharide-chelates of zinc with anti-tumor activity | |
| CN108395531A (en) | It is a kind of package nanogold particle amphoteric ion and morpholine modification Polyamidoamine Dendrimers preparation method | |
| OMENN | Ectopic polypeptide hormone production by tumors | |
| Cheng et al. | Protein stabilized polymeric nanoparticles inspired relay drug delivery for tackling post-chemotherapeutic metastasis | |
| CN108686220A (en) | A kind of antitumor agent for thyroid cancer | |
| Lyu et al. | Promoting neural differentiation of embryonic stem cells using β-cyclodextrin sulfonate | |
| CN106188537B (en) | A kind of PEI compounds of modification and its preparation method and application | |
| Xie et al. | A Cascade‐Targeted Enzyme‐Instructed Peptide Self‐Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death | |
| Liu et al. | Disulfide‐Bridged Dendritic Organosilicas‐Based Biodegradable Molecularly Imprinted Polymers for Multiple Targeting and pH/Redox‐Responsive Drug Release toward Chemical/Photodynamic Synergistic Tumor Therapy | |
| CN204848711U (en) | Domestic fungus extraction of polysaccharide device | |
| Bao et al. | Record‐High Ultrasound‐Sensitive NO Nanogenerators for Cascade Tumor Pyroptosis and Immunotherapy | |
| Liu et al. | Mitochondrial targeting half-sandwich iridium (III) and ruthenium (II) dppf complexes and in vitro anticancer assay | |
| Liu et al. | Analysis of α-amylase inhibitor from corni fructus by coupling magnetic cross-linked enzyme aggregates of α-amylase with HPLC–MS | |
| CN102772806B (en) | Application of micromolecular nucleic acid miR-302 for treating or preventing testicular cancer | |
| Ke et al. | Controllable DNA condensation through cucurbit [6] uril in 2D pseudopolyrotaxanes | |
| Nagasawa et al. | Effects of motherwort (Leonurus sibiricus L) on preneoplastic and neoplastic mammary gland growth in multiparous GR/A mice. | |
| CN106220651B (en) | A kind of class of anthrone containing amino oxygen functionalization graphene material and preparation method thereof and as the application prepared on antitumor drug | |
| CN112716947A (en) | Application of gamma-dehydroharmine extracted and separated from peganum harmala in preparing medicine for inhibiting gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181023 |
|
| RJ01 | Rejection of invention patent application after publication |